DE10306179A1 - Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe - Google Patents
Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe Download PDFInfo
- Publication number
- DE10306179A1 DE10306179A1 DE10306179A DE10306179A DE10306179A1 DE 10306179 A1 DE10306179 A1 DE 10306179A1 DE 10306179 A DE10306179 A DE 10306179A DE 10306179 A DE10306179 A DE 10306179A DE 10306179 A1 DE10306179 A1 DE 10306179A1
- Authority
- DE
- Germany
- Prior art keywords
- stroke
- dipyridamole
- angiotensin
- antagonist
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960002768 dipyridamole Drugs 0.000 title claims abstract description 34
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 28
- 229940123413 Angiotensin II antagonist Drugs 0.000 title claims abstract description 17
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 17
- 150000003839 salts Chemical class 0.000 title claims description 8
- 208000006011 Stroke Diseases 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 14
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 8
- 229960005187 telmisartan Drugs 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- RYSMHWILUNYBFW-GRIPGOBMSA-N 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](N)[C@H]1O RYSMHWILUNYBFW-GRIPGOBMSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen radicals Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10306179A DE10306179A1 (de) | 2003-02-13 | 2003-02-13 | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| US10/770,971 US20040214802A1 (en) | 2003-02-13 | 2004-02-03 | Dipyridamole, acetylsalicylic acid, and angiotensin II antagonist pharmaceutical compositions |
| ES04709596T ES2308147T3 (es) | 2003-02-13 | 2004-02-10 | Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de un accidente cerebrovascular. |
| PL378204A PL378204A1 (pl) | 2003-02-13 | 2004-02-10 | Zastosowanie dipirydamolu w kombinacji z kwasem acetylosalicylowym i antagonistą angiotensyny II do zapobiegania udarom |
| DE602004013937T DE602004013937D1 (de) | 2003-02-13 | 2004-02-10 | Kombinationspräparate zur verhinderung von schlagand einen atii antagonisten enthalten |
| AU2004212305A AU2004212305A1 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention |
| YUP-2005/0618A RS20050618A (sr) | 2003-02-13 | 2004-02-10 | Upotreba dipiridamola u kombinaciji sa acetilsalicilnom kiselinom i antagonistom angiotenzina ii za prevenciju moždanog udara |
| EP04709596A EP1603573B8 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| DK04709596T DK1603573T3 (da) | 2003-02-13 | 2004-02-10 | Anvendelse af dipyridamol i kombination med acetylsalicylsyre og en angiotensin II-antagonist til forebyggelse af slagtilfælde |
| SI200430789T SI1603573T1 (sl) | 2003-02-13 | 2004-02-10 | Uporaba dipiridamola v kombinaciji z acetilsalicilno kislino in antagonistom angiotenzina II za preprečevanje kapi |
| AT04709596T ATE395921T1 (de) | 2003-02-13 | 2004-02-10 | Kombinationspräparate zur verhinderung von schlaganfällen, welche dipyridamole, acetylsalicylsäure und einen atii antagonisten enthalten |
| US10/544,239 US20070004687A1 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ll antagonist for stroke prevention |
| UY28182A UY28182A1 (es) | 2003-02-13 | 2004-02-10 | Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular |
| CA002515941A CA2515941A1 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| MXPA05008572A MXPA05008572A (es) | 2003-02-13 | 2004-02-10 | Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular. |
| PT04709596T PT1603573E (pt) | 2003-02-13 | 2004-02-10 | Utilização de dipiridamole em combinação com ácido acetilsalicílico e um antagonista de angiotensuna ii para a prevenção de acidente vascular cerebral |
| PCT/EP2004/001208 WO2004071385A2 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| BR0407457-2A BRPI0407457A (pt) | 2003-02-13 | 2004-02-10 | Uso do dipiridamol com ácido acetilsalicìlico e um antagonista da angiotensina ii na prevenção de acidente vascular cerebral (avc) |
| JP2006501788A JP2006517557A (ja) | 2003-02-13 | 2004-02-10 | 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用 |
| NZ542302A NZ542302A (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention |
| CNA2004800041078A CN1750830A (zh) | 2003-02-13 | 2004-02-10 | 双嘧达莫与乙酰水杨酸及血管紧张素ⅱ拮抗剂的组合在预防中风中的应用 |
| EA200501231A EA200501231A1 (ru) | 2003-02-13 | 2004-02-10 | Применение дипиридамола в комбинации с ацетилсалициловой кислотой и антагонистом ангиотензина ii для предупреждения инсульта |
| HR20050713A HRP20050713A2 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| KR1020057014826A KR20050100676A (ko) | 2003-02-13 | 2004-02-10 | 아세틸살리실산 및 안지오텐신 ⅱ 길항제와 배합된디피리다몰의 뇌졸중 예방을 위한 용도 |
| EP06121998A EP1733729A1 (en) | 2003-02-13 | 2004-02-10 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| PE2004000151A PE20050191A1 (es) | 2003-02-13 | 2004-02-11 | Composicion farmaceutica que comprende dipiridamol, acido acetilsalicilico y un antagonista de angiotensina ii |
| TW093103344A TW200501957A (en) | 2003-02-13 | 2004-02-12 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention |
| ARP040100446A AR043173A1 (es) | 2003-02-13 | 2004-02-13 | Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular |
| UAA200508697A UA83481C2 (uk) | 2003-02-13 | 2004-10-02 | Фармацевтична композиція дипіридамолу в комбінації з ацетилсаліциловою кислотою й антагоністом ангіотензину ii та її застосування для запобігання інсульту |
| EC2005005963A ECSP055963A (es) | 2003-02-13 | 2005-08-11 | Uso de dipiradamol en combinación con acido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular |
| NO20054216A NO20054216L (no) | 2003-02-13 | 2005-09-12 | Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag |
| ZA200505956A ZA200505956B (en) | 2003-02-13 | 2006-02-09 | Use of dipyridamoi in combination with acetylsalicyclic acid and an angiotensin II antagonist for stroke prevention |
| US11/478,184 US20060241089A1 (en) | 2003-02-13 | 2006-06-29 | Dipyridamole, acetylsalicylic acid, and angiotensin II antagonist pharmaceutical compositions |
| US11/958,499 US20080113949A1 (en) | 2003-02-13 | 2007-12-18 | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention |
| US12/014,181 US20080188497A1 (en) | 2003-02-13 | 2008-01-15 | Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10306179A DE10306179A1 (de) | 2003-02-13 | 2003-02-13 | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| EP03018212 | 2003-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10306179A1 true DE10306179A1 (de) | 2004-08-26 |
Family
ID=32870338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10306179A Withdrawn DE10306179A1 (de) | 2003-02-13 | 2003-02-13 | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| DE602004013937T Expired - Fee Related DE602004013937D1 (de) | 2003-02-13 | 2004-02-10 | Kombinationspräparate zur verhinderung von schlagand einen atii antagonisten enthalten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004013937T Expired - Fee Related DE602004013937D1 (de) | 2003-02-13 | 2004-02-10 | Kombinationspräparate zur verhinderung von schlagand einen atii antagonisten enthalten |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20040214802A1 (enExample) |
| EP (2) | EP1733729A1 (enExample) |
| JP (1) | JP2006517557A (enExample) |
| KR (1) | KR20050100676A (enExample) |
| CN (1) | CN1750830A (enExample) |
| AR (1) | AR043173A1 (enExample) |
| AT (1) | ATE395921T1 (enExample) |
| AU (1) | AU2004212305A1 (enExample) |
| BR (1) | BRPI0407457A (enExample) |
| CA (1) | CA2515941A1 (enExample) |
| DE (2) | DE10306179A1 (enExample) |
| DK (1) | DK1603573T3 (enExample) |
| EA (1) | EA200501231A1 (enExample) |
| EC (1) | ECSP055963A (enExample) |
| ES (1) | ES2308147T3 (enExample) |
| HR (1) | HRP20050713A2 (enExample) |
| MX (1) | MXPA05008572A (enExample) |
| NO (1) | NO20054216L (enExample) |
| NZ (1) | NZ542302A (enExample) |
| PE (1) | PE20050191A1 (enExample) |
| PL (1) | PL378204A1 (enExample) |
| PT (1) | PT1603573E (enExample) |
| RS (1) | RS20050618A (enExample) |
| SI (1) | SI1603573T1 (enExample) |
| TW (1) | TW200501957A (enExample) |
| UA (1) | UA83481C2 (enExample) |
| UY (1) | UY28182A1 (enExample) |
| WO (1) | WO2004071385A2 (enExample) |
| ZA (1) | ZA200505956B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| CA2437709A1 (en) * | 2003-08-08 | 2005-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events |
| JP2005060359A (ja) * | 2003-08-13 | 2005-03-10 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用 |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| WO2009100534A1 (en) * | 2008-02-14 | 2009-08-20 | Kardiatech, Inc. | Combination therapy to treat vascular disorders |
| US20100069326A1 (en) * | 2008-02-14 | 2010-03-18 | Wasimul Haque | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders |
| WO2010097501A2 (en) * | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| TWI725008B (zh) * | 2015-01-28 | 2021-04-21 | 瑞采生技有限公司 | 用於增強ＰＰＡＲγ表現及核轉位之化合物及其醫療用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031458A (en) * | 1958-02-05 | 1962-04-24 | Ciba Pharm Prod Inc | Isoindolines |
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| US3317279A (en) * | 1963-03-15 | 1967-05-02 | Pennsalt Chemicals Corp | Polymorph of calcium disilicide and its method of preparation |
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| US4318477A (en) * | 1980-09-22 | 1982-03-09 | Kerpe Stase Z | Pharmaceutical package |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| DE3627423A1 (de) | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| EP1013273A1 (en) | 1998-12-23 | 2000-06-28 | Novartis AG | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| JP2002138054A (ja) * | 2000-08-25 | 2002-05-14 | Takeda Chem Ind Ltd | フィブリノーゲン低下剤 |
| JP2002293742A (ja) * | 2001-01-29 | 2002-10-09 | Takeda Chem Ind Ltd | 鎮痛・抗炎症剤 |
| JP2003212758A (ja) * | 2001-03-16 | 2003-07-30 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
-
2003
- 2003-02-13 DE DE10306179A patent/DE10306179A1/de not_active Withdrawn
-
2004
- 2004-02-03 US US10/770,971 patent/US20040214802A1/en not_active Abandoned
- 2004-02-10 CA CA002515941A patent/CA2515941A1/en not_active Abandoned
- 2004-02-10 BR BR0407457-2A patent/BRPI0407457A/pt not_active IP Right Cessation
- 2004-02-10 PL PL378204A patent/PL378204A1/pl not_active Application Discontinuation
- 2004-02-10 AT AT04709596T patent/ATE395921T1/de not_active IP Right Cessation
- 2004-02-10 PT PT04709596T patent/PT1603573E/pt unknown
- 2004-02-10 US US10/544,239 patent/US20070004687A1/en not_active Abandoned
- 2004-02-10 AU AU2004212305A patent/AU2004212305A1/en not_active Abandoned
- 2004-02-10 EA EA200501231A patent/EA200501231A1/ru unknown
- 2004-02-10 CN CNA2004800041078A patent/CN1750830A/zh active Pending
- 2004-02-10 JP JP2006501788A patent/JP2006517557A/ja active Pending
- 2004-02-10 NZ NZ542302A patent/NZ542302A/en unknown
- 2004-02-10 DE DE602004013937T patent/DE602004013937D1/de not_active Expired - Fee Related
- 2004-02-10 RS YUP-2005/0618A patent/RS20050618A/sr unknown
- 2004-02-10 ES ES04709596T patent/ES2308147T3/es not_active Expired - Lifetime
- 2004-02-10 KR KR1020057014826A patent/KR20050100676A/ko not_active Withdrawn
- 2004-02-10 EP EP06121998A patent/EP1733729A1/en not_active Withdrawn
- 2004-02-10 UY UY28182A patent/UY28182A1/es not_active Application Discontinuation
- 2004-02-10 SI SI200430789T patent/SI1603573T1/sl unknown
- 2004-02-10 MX MXPA05008572A patent/MXPA05008572A/es active IP Right Grant
- 2004-02-10 WO PCT/EP2004/001208 patent/WO2004071385A2/en not_active Ceased
- 2004-02-10 DK DK04709596T patent/DK1603573T3/da active
- 2004-02-10 EP EP04709596A patent/EP1603573B8/en not_active Expired - Lifetime
- 2004-02-10 HR HR20050713A patent/HRP20050713A2/xx not_active Application Discontinuation
- 2004-02-11 PE PE2004000151A patent/PE20050191A1/es not_active Application Discontinuation
- 2004-02-12 TW TW093103344A patent/TW200501957A/zh unknown
- 2004-02-13 AR ARP040100446A patent/AR043173A1/es unknown
- 2004-10-02 UA UAA200508697A patent/UA83481C2/uk unknown
-
2005
- 2005-08-11 EC EC2005005963A patent/ECSP055963A/es unknown
- 2005-09-12 NO NO20054216A patent/NO20054216L/no not_active Application Discontinuation
-
2006
- 2006-02-09 ZA ZA200505956A patent/ZA200505956B/en unknown
- 2006-06-29 US US11/478,184 patent/US20060241089A1/en not_active Abandoned
-
2007
- 2007-12-18 US US11/958,499 patent/US20080113949A1/en not_active Abandoned
-
2008
- 2008-01-15 US US12/014,181 patent/US20080188497A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60037277T2 (de) | Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen | |
| DE60202278T2 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
| DE3490583T1 (de) | Analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung | |
| EP1477166A1 (de) | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis | |
| US20080113949A1 (en) | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention | |
| DE3390114T1 (de) | Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung | |
| DE3390116C2 (de) | Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel | |
| DE60301862T2 (de) | Kombinationsbehandlung bei akutem myokardinfarkt | |
| DE60206169T2 (de) | Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff | |
| DE69935865T2 (de) | Endothelin-niveau senkende mittel | |
| DE602004005000T2 (de) | Methode zur behandlung von niereninsuffizienz | |
| WO2007115997A2 (de) | Kombinationspräparate aus modafinil, ritalin und topiramat bei kokainabhängigkeit und/oder zur behandlung von impulskontrollstörungen | |
| DE69421174T2 (de) | Verwendung von adenosin zur herstellung eines arzneimittels zur behandlung entzüdlicher reaktionen der lunge | |
| EP2244693B1 (de) | Mittel zur intraartikulären injektion | |
| US20080275011A1 (en) | Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events | |
| DE10119680A1 (de) | Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation | |
| HUE030408T2 (en) | Use of pidotimod for topical treatment of atopic dermatitis | |
| DE60210804T2 (de) | Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit | |
| DE19732323A1 (de) | Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben | |
| KR20050018330A (ko) | 혈관장애의 치료 및 예방을 위한 디피리다몰,아세틸살리실산 및 안지오텐신 ⅱ 길항제의 용도 | |
| WO1999017756A2 (de) | Methode zur verhinderung der transplantatabstossung | |
| JP2005060359A (ja) | 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用 | |
| AT389999B (de) | Verfahren zur herstellung analgetischer und antiinflammatorischer mittel | |
| MXPA03007462A (es) | Uso de dipiridamol, acido acetilsalicilico y un antagonista de la angiotensina ii para el tratamiento y la prevencion de eventos vasculares. | |
| DE2549998A1 (de) | Mittel zur hemmung der thrombozytenaggregation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |